The Silicon Review ^Asia

Hyderabad based pharmaceutical manufacturing company, Aurobindo Pharma Limited, has been a bit slow on the acquisition front. It had made some key acquisitions in the past and is now considering to add a few branded products to its subsidiary, Acrotech Biopharma’s portfolio. After acquiring a portfolio of seven oncology injectable products from US-based Spectrum Pharmaceuticals Inc for $300 million, Acrotech Biopharma hopes to generate a revenue of around $100 million from it for the initial year after the completion of the transaction for Aurobindo.

At the Q3FY19 results conference call, N Govindarajan, Managing Director of Aurobindo Pharma, said that they keep evaluating their domestic business sometimes, but now they are prioritising to integrate what they have acquired. This could take time and therefore, they will just stick to adding a couple of branded products into the portfolio instead of making any large acquisition. He also said that Aurobindo Pharma will be overseeing the dietary supplements segment in India in the long-term as well as file approvals for at least two biosimilar products in 2020.“Subsequent year we should get approval as far as Europe is concerned as approval time is around 210-days if everything is in line in terms of the filing. As far as US is concerned, you should estimate around 12 to 18 months for approval from the date of filing”, he added.

Aurobindo Pharma hopes to commercialise its product in the Chinese market after two and a half years. Presently, it has received the permits for building its facility, set to be completed within a year.